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In William Silverman’s book, “Where’s the 
evidence” (1), he elegantly espouses the 
need for, and the contributions of, good 
research to improve clinical outcomes. But 
with respect to technological advancements, 
he challenges us and future generations 
on where the line between “knowing (the 
acquisition of new knowledge) and ‘doing’ 
(the application of the new knowledge)” 
should be drawn (1). Just because we can 
do things, does not mean that it should be 
done without considering the moral and 
social consequences.
On a world-wide scale, the respiratory 
system is a particularly important field in 
childhood. Key reasons include; (i) pneu-
monia remains the biggest killer of children, 
despite massive advances in medicine, vacci-
nations, and public health; (ii) unlike some 
other organs, the lung continues to grow 
at least till 7–8 years of age, if not longer; 
and (iii) pulmonary immunity and respira-
tory phenotype is influenced by genetic-
environmental interaction that commence 
very early in life (possibly in utero). Thus, 
it is highly biologically plausible that many 
common conditions in adulthood emerge 
from early childhood factors (2). There is 
indeed increasing evidence that a substantial 
proportion of lung disease in adults (such as 
chronic obstructive lung disease and bron-
chiectasis) has its roots in childhood (where 
it is potentially reversible) (3, 4). To reduce 
the world-wide burden of chronic respira-
tory illness, a greater focus on children’s 
lung and generic health is required. Many, 
if not most of these diseases, are potentially 
modifiable through clinically based inter-
ventions or are preventable.
Yet, there is comparatively little research 
for the huge word-wide burden of respira-
tory illnesses. This is compounded by the 
fact that the socio-economic gradient is 
a factor in many diseases of the respira-
tory system, i.e., people in resource-poor 
countries and the underprivileged in 
 resource-rich  countries have the highest 
burden of respiratory illness. While this rep-
resents a challenge it also presents an oppor-
tunity for those in resource-rich countries 
to find interventions that can be applied to 
resource-poor settings.
Indeed, while major advances in child 
health are likely to follow improvements in 
education and reductions in poverty, a sys-
tematic overview of interventions address-
ing the social determinants of health found 
a striking lack of reliable evaluations (5). 
Where evidence was available, the health 
improvement associated with interven-
tions was modest or uncertain (5). Thus 
advances in health care for important child-
hood conditions that are achievable within 
a much shorter timeframe remain essential. 
Interventions that can be feasibly imple-
mented remain vital to improve world-wide 
lung health. Also, while the greater world-
wide challenge is to improve lung health 
in developing countries, respiratory illness 
remains the most common cause of hospi-
talization in children in affluent countries. 
This highlights the fact that while it remains 
imperative that to tackle the social deter-
minants of health, it is insufficient to just 
focus on it. Nevertheless, equity of service 
is important. Even in affluent countries, 
equity of high quality service for differ-
ent diseases [such as comparing service for 
people with cystic fibrosis (CF) with that 
for those with non-CF bronchiectasis] and 
different settings (e.g., urban vs. remote set-
tings) remains problematic and a challenge.
While there is little doubt that solutions 
to improving lung health will need to include 
technological advancements, in some set-
tings substantial improvements may be 
possible with less expensive programs. This 
could occur through challenging existing 
paradigms. The major improvement in 
longevity of people with CF over the last 
three decades is not related to major tech-
nological or genetic breakthroughs, but 
related to improved clinical care through 
better attention to nutrition, airway clear-
ance and intensive treatment of infections. 
By changing the paradigm of a defeat-
ist approach of “minimal treatment” to a 
“best possible care of intensive treatment,” 
a reduction in early morbidity and mortality 
have occurred in CF in affluent countries 
and non-CF bronchiectasis in Indigenous 
populations in affluent countries.
Researchers will constantly be reminded 
that despite the massive investment in 
research in asthma pathophysiology, the 
largest contributor to improvements in 
asthma morbidity and mortality in affluent 
countries was patient-centered education 
and better use of available current medica-
tions (6, 7). It is indeed ironical that while 
many renowned researchers discovered 
and paddled the importance of allergy and 
its role in the pathophysiology in the field 
of asthma over decades, the prevalence of 
asthma and its severity in affluent countries 
was actually declining. This highlights the 
need for a multi-disciplinary collaborative 
approach to make a real impact, as well as 
the importance of a translational approach 
in research.
Research in other areas such as the 
diagnosis and treatment of pneumonia 
and its consequences are required. While 
it may appear simple with the use of chest 
radiography and antibiotics, issues of how 
best to diagnose and treat so as to prevent 
future chronic lung disease such as COPD 
(8) and bronchiectasis (9), especially in 
resource-poor settings, remains a great 
challenge. While COPD is related with 
tobacco smoke exposure in some people, a 
large proportion of COPD is unrelated to 
tobacco smoke.
Studies on how best to prevent lung dis-
eases, above and beyond tobacco control is 
one possible key in improving future lung 
health of children. Factors that govern 
lung development and growth, pulmonary 
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•	 Can	and	how	will	the	blooming	world	
of “omics” contribute to the betterment 
of lung health?
•	 Can	 safe	 and	 feasible	 interventions	 to	
reverse lung disease in childhood (such 
as bronchopulmonary dysplasia) be 
found?
•	 Will	 current	 research	 on	 the	 fetal	 tre-
atment of pulmonary defects prevent 
future congenital lung anomalies?
•	 Can	 we	 expect	 the	 combination	 of	
experimental studies, computational 
models and nanotechnologies to unveil 
the remaining secrets of lung and 
function?
•	 Will	 robust	 gene	 expression	 signa-
ture or biomarkers to diagnose and/or 
monitor the various lung diseases be 
discovered?
•	 Which	mechanisms	 and	 interventions	
are most important in optimizing lung 
growth and development?
•	 Can	 clinicians,	 public	 health	 experts,	
the pharmaceutical industry, and poli-
tical masters join forces to abolish 
the barriers to improving global lung 
health?
•	 Will	 the	 dream	 of	 equal	 high	 quality	
and holistic care irrespective of setting 
and disease become a reality?
All researchers and scientists inter-
ested in contributing to improving lung 
health especially that affecting the most 
disadvantaged in the world will find that 
an open platform for mutual exchanges 
beneficial. One of the aims of “Frontiers 
in Pediatric Pulmonology” is to fulfill this 
role and attract the most visionary people 
to discover and share unexpected insights, 
breakthroughs and advance this field for the 
betterment of humanity. The coming years 
will give us the opportunity foster scientific 
and affordable technological innovations 
to solve respiratory problems in children 
which will also reduce adult lung disease. 
In doing so, it would also impact on future 
cardiovascular health as chronic wet/pro-
ductive cough is a known independent risk 
factor of cardiovascular disease (10).
innate and adaptive immunity and their 
relationship with the lung microbiome, 
metagenomics, and metabolomics (etc) will 
likely contribute to future clinical interven-
tions and hence lung health.
Recent studies have shown that some 
 respiratory disease and infection have 
unique airway and/or systemic molecular 
signatures. These gene expression signa-
tures may be a powerful tool allowing earlier 
detection of certain diseases at their earli-
est stages before overt clinical manifestation 
when they are most preventable. Molecular 
signatures and biomarkers represent the 
future of many fields of medicine, includ-
ing respiratory medicine where disease 
diagnosis, treatment, monitoring, and pre-
vention may be guided by a patient’s unique 
composition and/or response. However, all 
advances need to be balanced with evidence 
that is not driven by those interested only 
in financial procurement.
“Frontiers in Pediatric Pulmonology” 
will stimulate and support researchers 
involved in the most recent advances in the 
field with a translational application. The 
grand challenge for clinicians and research-
ers in years to come include:
•	 Discovering	 affordable	 technological	
advances for point of care testing of 
common illness such as pneumonia 
that allows targeting of better use of 
antibiotics;
•	 How	 to	 interest	 researchers	 to	 under-
take studies and granting bodies to 
fund studies on common conditions 
such as acute cough and pneumonia?
•	 How	best	 to	 support	 behavior	 changes	
that lead to improving adherence to 
effective evidence-based interventions 
such as the use of inhaled corticoste-
roids for chronic asthma and hygiene for 
reducing acute respiratory infections?
•	 What	 are	 the	 best	 and	 long	 lasting	
interventions to prevent the uptake of 
tobacco smoke in the young?
•	 Can	 new	 drug	 discoveries	 that	 are	
effective and safe, be more equitably 
available?
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